KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Common Equity (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Common Equity for 13 consecutive years, with $581.8 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 22.94% to $581.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $581.8 million through Dec 2025, down 22.94% year-over-year, with the annual reading at $581.8 million for FY2025, 22.94% down from the prior year.
  • Common Equity for Q4 2025 was $581.8 million at Xenon Pharmaceuticals, up from $559.5 million in the prior quarter.
  • The five-year high for Common Equity was $927.9 million in Q4 2023, with the low at $248.9 million in Q3 2021.
  • Average Common Equity over 5 years is $639.8 million, with a median of $666.7 million recorded in 2023.
  • The sharpest move saw Common Equity surged 220.99% in 2021, then fell 29.87% in 2025.
  • Over 5 years, Common Equity stood at $550.0 million in 2021, then skyrocketed by 31.17% to $721.5 million in 2022, then rose by 28.61% to $927.9 million in 2023, then decreased by 18.65% to $754.9 million in 2024, then decreased by 22.94% to $581.8 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $581.8 million, $559.5 million, and $634.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.